CJC-1295 without DAC: a GHRH analogue that still pulses

CJC-1295 without DAC is tetrasubstituted GRF(1–29), a laboratory analogue of the hypothalamic peptide that tells a somatotroph to release growth hormone. Native growth-hormone-releasing hormone is forty-four residues; the first twenty-nine, amidated, already occupy the receptor with full efficacy. Blood destroys that twenty-nine-mer in minutes. Dipeptidyl peptidase-IV — DPP-IV, the same enzyme that chews GLP-1 after a meal — cleaves the Ala2–Asp3 bond, a truncation that abolishes agonism. Chemists therefore swapped four positions — D-Ala2, Gln8, Ala15, Leu27 — so the chain lasts tens of minutes rather than minutes, and rather than days. Tens of minutes is still a pulse on a pituitary clock. Adding a Drug Affinity Complex, an N-ε-maleimidopropionyl-lysine that Michael-adds to albumin, would stretch the same backbone into a multi-day drip. Teichman and colleagues showed what that drip does: GH and IGF-1 stay up. Useful for some designs. Wrong if the question is physiology. We stock the version without the maleimide because the pulse is the message, and flattening the pulse changes the sentence the liver writes.

In short. This analogue is a short copy of the brain peptide that tells the pituitary to release growth hormone. It lasts tens of minutes, on purpose, so it can still come in bursts.

A peptide catalogue with a journal attached has a duty to say which molecule is in the cake. The trade name CJC-1295 was coined for ConjuChem's albumin-conjugating analogue, the one with the Drug Affinity Complex on it. Modified GRF(1–29), sold widely as CJC-1295 without DAC, is the tetrasubstituted twenty-nine-mer and is a different object. Same receptor. Different clock. The neighbouring essay on this desk is the whole growth-hormone axis: GHRH, ghrelin, somatostatin, the 191-residue ligand, hepatic IGF-1. This piece is one microphone on that axis, written at the length the analogue actually needs. It's the native peptide, the truncation, the enzyme, the four substitutions, the maleimide we left off, the licensed neighbour tesamorelin, and the second G protein that makes a large pulse when a secretagogue is also present. It isn't a protocol. Papers that already ran GHRH analogues in slices and in animals are in PubMed, with concentrations and sampling intervals. Stay here if you wanted the chemistry and the receptor explained.

In short. The name CJC-1295 first belonged to a long-acting version stuck to blood protein. The version in this essay is the short one, built to still pulse.

The somatotroph — the pituitary cell that stores growth hormone — doesn't read captions. It reads a ratio in portal blood, a cyclic-AMP increment, a calcium current, and a readily-releasable pool of dense-core granules packed with the 191-residue four-helix bundle. GHRH is the go. Somatostatin is the stop. Ghrelin, occupying GHS-R1a, turns the volume up. Johannes Veldhuis spent a career showing that the product of that ratio is a digital signal: night-time bursts, a low interpulse baseline, suppression by hyperglycaemia, amplification by fasting. A GHRH analogue is a probe at the first of those receptors. How long it sits there decides whether the somatotroph still sees peaks and troughs, or whether it sees a plateau that never quite returns to baseline. Four amino acids decide the first of those clocks. A maleimide on a lysine decides the second. This essay is the argument for the first clock, named at every floor, with the papers you'd want to cite if you were running the analogue. The athlete in the figure is a late readout. The receptor is early.

In short. Pituitary cells release growth hormone in bursts, mostly at night. How long this analogue lasts decides whether those bursts still have quiet gaps between them.

The hypothalamus writes growth-hormone-releasing hormone into the portal capillaries that bathe the anterior pituitary, a millimetre or two away. The neurons sit mainly in the arcuate nucleus. The peptide is forty-four residues in the human, processed from a larger precursor, amidated at the C-terminus. Guillemin, Schally, Rivier, Vale, Thorner and colleagues isolated it from tumour and hypothalamic extracts in the early 1980s after a decade of false starts and a graveyard of putative GRFs that did not survive a pituitary-cell assay. Science, 1982, Guillemin's group; Nature, 1982, Vale and Rivier's. Those papers turned a physiological inference — something from the hypothalamus releases GH — into a sequence you could synthesise. The clinical and physiological literature that followed is why a GHRH analogue is a serious research object rather than a caption. Length, here, isn't decoration. The receptor's extracellular domain reads a defined face of the peptide, and chemists have known which end does the activating work since the isolation papers were still warm.

In short. GHRH is a 44-amino-acid message from the brain to the pituitary. It was isolated in 1982, and the first twenty-nine amino acids already do the full job.

GRF(1–29)-NH2 is the truncation that built every laboratory GHRH analogue that matters. Take the first twenty-nine residues of the forty-four, amidate the new C-terminus, and the class-B receptor still sees full agonism. The C-terminal fifteen residues of native GHRH contribute to binding and to circulating half-life in some assays; they aren't required for efficacy at GHRHR. That's a structural fact about a secretin-family receptor, not a marketing convenience. The large N-terminal extracellular domain of GHRHR catches the C-terminal half of a longer peptide; the transmembrane bundle reads the N-terminus, which is why chopping the N-terminus makes an antagonist and chopping the far C-terminus does not. Modified GRF(1–29) sits on that twenty-nine-residue backbone. Tesamorelin, the licensed neighbour, sits on the full forty-four with a hexenoyl cap. Two lengths, one receptor family, two design decisions. Treating 'GHRH analogue' as one substance already mixes those objects, and will misread both a certificate of analysis and a package insert.

In short. The first twenty-nine amino acids of GHRH are enough to switch the pituitary receptor fully on. That shorter chain is the backbone of this analogue.

Portal blood is the medium, and it isn't a sample from a cubital vein. Concentrations in the long portal vessels are high, pulsatile, and largely cleared before they reach the arm. A peripheral GHRH measurement is therefore a poor photograph of what the somatotroph just heard. Clinical tests that still use GHRH, often with arginine to suppress somatostatin, are provocations: they ask whether the pituitary can still answer, not what the hypothalamus whispered an hour ago. The arcuate GHRH neuron is itself gated. Slow-wave sleep is the largest physiological window. Fasting amplifies. Sex steroids shape amplitude and frequency. Thyroid hormone is permissive for GH synthesis; a hypothyroid somatotroph writes fewer granules. A dense inhibitory innervation from periventricular somatostatin neurons is the stop that has to drop before a pulse is allowed through. A pulse is a hypothalamic computation before it is a pituitary secretion. A laboratory analogue arriving from the periphery occupies one receptor in that village. The village is still there when the analogue arrives.

In short. The pituitary hears GHRH in a special local blood supply, in bursts, gated by sleep and other hormones. An analogue occupies one receptor in that whole village.

Somatostatin is the stop, and if you add a GHRH analogue without naming it you've described half of the hypothalamic sentence. Brazeau, Vale, Guillemin, Science 1973: a fourteen-residue cyclic peptide from hypothalamic extracts that inhibited growth-hormone release in pituitary cells, named for that job before its wider life as a gut and pancreatic hormone was mapped. A twenty-eight-residue N-terminally extended form exists and isn't a footnote in some tissues. On the somatotroph the relevant receptors are mainly SSTR2 and SSTR5, class-A GPCRs coupled to Gi. Adenylyl cyclase falls. Cyclic AMP falls. The L-type calcium current that GHRH had opened is opposed. Granule fusion slows. Somatostatin tone is high between pulses and drops as a pulse is allowed through. The go is therefore a double event: GHRH up and somatostatin down, arriving as a ratio. An analogue at GHRHR still has to live with that ratio. It can't repeal Gi. It can only raise the Gs side of a contest that the stop peptide is still fighting.

In short. Somatostatin is the brain's stop signal for growth hormone. It cuts the same internal alarm that GHRH raises, so a pulse is really a ratio of go to stop.

Genetic proofs keep the cascade in order, which is why they belong in an analogue essay and not only in a textbook. The little mouse carries a missense mutation in Ghrhr; it is GH-deficient and small, and it is why Mayo's clone of the receptor was more than a sequence on a gel. Human isolated GH deficiency type IB includes GHRHR mutations, particularly in consanguineous cohorts that paediatric endocrinology still cites. Laron syndrome is the next floor down: GHR mutations, high GH, very low IGF-1, a receptor that will not rotate and will not recruit JAK2. A GHRH analogue can't rescue Laron. A GH analogue can't rescue a missing STAT5b. Mecasermin, recombinant native IGF-1, is the licensed ligand when the cascade is broken below GHR, in a named paediatric indication. Catalogue modified GRF(1–29) isn't a rescue for a missing receptor it never meets. The genetics are here so the microphone stays labelled. Occupying GHRHR is a precise question. It's a useless question if the somatotroph, or the GH receptor, or STAT5b, is the floor that actually failed.

In short. Mutations show the cascade is ordered: this receptor, then growth hormone, then IGF-1. An analogue cannot fix a break at a floor it never reaches.

GHRHR is a class-B secretin-family GPCR, the same structural neighbourhood as GLP-1R, GIPR, GCGR and the secretin receptor itself. Seven transmembrane helices, a large N-terminal extracellular domain that captures the C-terminal half of the peptide, and a transmembrane pocket that reads the N-terminus. Occupancy rearranges the helices. The intracellular face becomes a guanine-nucleotide exchange factor for Gs. Mayo cloned the receptor in the early 1990s; Molecular Endocrinology, 1992. Inactivating mutations cause a rare isolated growth-hormone deficiency, which is the genetic proof that this protein isn't optional in the axis. Class B is a different extracellular architecture from the rhodopsin-like class A that GHS-R1a belongs to. A chemist who designs a GHRH analogue is designing against a hormone-binding ectodomain, not against a small-molecule cleft. That's why the first twenty-nine residues still matter, and why a five-residue ghrelin-receptor agonist can't be redescribed as a short GHRH. Two locks. Two ligand lengths. One granule downstream, if both locks turn.

In short. The GHRH receptor is a seven-helix protein in the same family as the gut-hormone receptors. Occupying it loads a stimulatory G protein called Gs.

Gs is the first amplifier. GTP-bound Gαs occupies adenylyl cyclase. Cyclic AMP rises, in somatotrophs, by enough to occupy protein kinase A. PKA phosphorylates CREB, which is the transcriptional half of a longer GHRH exposure, and phosphorylates the machinery that opens L-type voltage-gated calcium channels. Calcium enters. Local calcium at the granule is the proximate trigger for exocytosis of stored growth hormone. The granule is a dense-core vesicle packed with GH, already synthesised, waiting. A pulse, on the seconds-to-minutes clock, is mostly that fusion event. Hours of GHRH tone will also write more GH gene transcription, more granules, a larger readily-releasable pool. Two clocks, one receptor. A short-acting analogue asks the first clock. An albumin-conjugated analogue asks both, and then asks what the liver does with a flattened GH tone, which is a third question. Cyclic AMP is hydrolysed by phosphodiesterases. Somatostatin, via Gi, opposes the cyclase. The pulse is therefore a contest at the cyclase as well as a contest at the portal.

In short. GHRH raises a messenger called cAMP, which opens calcium channels so stored growth hormone can be released. A short analogue asks that quick release.

L-type calcium current is the sentence most brochure copy skips. Somatotrophs are electrically excitable. They fire action potentials. The depolarisation that GHRH and ghrelin both encourage, by different G proteins, opens Cav1 channels. The calcium that enters is the fusion signal. Block those channels with a dihydropyridine in a pituitary slice and the GH pulse collapses, which is old pharmacology and still a useful control if someone claims a GHRH analogue released hormone by a novel inner path. GHRH gets there through cAMP and PKA. Ghrelin gets there through Gq, phospholipase C, IP3, and a rise in intracellular calcium that also depolarises. The two paths converge on the same granule. That convergence is why co-application of a GHRH analogue and a GHS-R1a agonist releases more GH than either ligand alone, in slices and in animals, and why textbooks draw the large pulses as a combination. Synergy is a G-protein fact. Isolating each ligand is how you know which receptor did the work. Naming both concentrations is the standard the pituitary-slice papers already set.

In short. Both GHRH and ghrelin raise calcium inside the pituitary cell, by different routes, and growth-hormone granules then fuse. Together they make the large bursts.

Desensitisation is why more ligand isn't more signal forever, and it is one of the costs an albumin-conjugated analogue buys when it buys duration. Occupied GHRHR is phosphorylated by GRKs, binds β-arrestin, and is internalised. Recycle or degrade, depending on the duration and the cell. A somatotroph that sees continuous GHRH tone will, within hours, present fewer receptors and a smaller cAMP increment per molecule of ligand. That's ordinary GPCR biology, the same arithmetic Lefkowitz spent a career on, applied to a class-B receptor whose ligand in life is a pulse. Tesamorelin, dosed once daily as a licensed medicine, lives with that trade because its indication asked for a sustained IGF-1 rise and a visceral-fat readout, not a copy of nocturnal physiology. A research analogue without DAC was built for the other trade: occupy, raise cAMP, open the calcium current, fuse granules, and then get out of the way so the receptor census and the trough can recover. Getting out of the way is a pharmacokinetic property. It's also a scientific decision.

In short. If GHRH stays high for too long, the receptor is pulled inside and the cell hears less. A short analogue leaves so hearing can recover.

Dipeptidyl peptidase-IV is a serine protease on endothelial cells and in plasma that removes two N-terminal residues from peptides with a proline or alanine in the second position. Native GHRH has alanine at position 2 and aspartic acid at position 3. The enzyme cleaves that Ala2–Asp3 bond within minutes in plasma. The truncated product doesn't occupy GHRHR as an agonist. That's why a forty-four-residue hypothalamic peptide, potent at the receptor, is almost useless as a peripheral ligand: the journey from a syringe to a somatotroph is long enough for DPP-IV to finish the job. Mentlein and colleagues mapped this cleavage family in the 1990s on incretins; the same enzyme is why native GLP-1 dies in about two minutes and why sitagliptin exists. GHRH and GLP-1 aren't the same hormone. They share an enemy. Talking about 'boosting GHRH' without saying whether you mean the enzyme, the receptor, or a substituted analogue hasn't chosen a mechanism. The analogue in this essay chose the receptor, and chose to survive the enzyme by substitution rather than by inhibiting it.

In short. An enzyme in blood called DPP-IV cuts native GHRH in minutes and turns it off. That is why chemists had to change the chain before it could be a useful laboratory ligand.

Sitagliptin occupies the enzyme so more native incretin survives a meal. That's a different therapeutic idea from injecting a substituted analogue, and it produces a different magnitude on a different axis. Nobody honest is running a DPP-IV inhibitor as a GHRH secretagogue protocol, because the enzyme has many substrates and because the hypothalamic peptide isn't sitting in peripheral plasma waiting to be spared. The analogue strategy accepts that native GHRH is the wrong pharmacokinetic object once it leaves the portal. It builds a chain the enzyme cannot eat as fast. Modified GRF(1–29) stops at that first move: resist the enzyme, keep the pulse. Fatty-acylated incretins go further and add a lipid so albumin will carry them through the week. ConjuChem's Drug Affinity Complex went further still, with a covalent maleimide rather than a reversible lipid handle. Three answers to a short half-life, three design goals. GHRH wants a peak and a trough. A weekly incretin wants a week of tone. Copying the incretin half-life trick onto GHRH is how you accidentally run the Teichman experiment when you thought you were running a pulse.

In short. Blocking the enzyme and rebuilding the hormone are different ideas. This analogue rebuilds GHRH just enough to last a pulse, not a week.

Minutes, as a half-life, aren't a moral failure of the native peptide. They're how a hypothalamic signal stays local. Portal concentrations can be high because the travel distance is millimetres and the exposure is brief. Spill the same peptide into the general circulation and the enzyme, the kidney and dilution finish what anatomy started. A laboratory that wants a peripheral probe therefore has to cheat the enzyme without cheating the pulse. That's a narrower brief than 'make it last'. Lasting tens of minutes, after a subcutaneous or intravenous dose, is long enough to occupy GHRHR through a burst and short enough that a trough can still happen before the next dose or before the next endogenous wave. Lasting days is a different brief, and it was written for a different question: what does flattened GHRH tone do to IGF-1 and to body composition. Both briefs are lawful. They aren't interchangeable, and a certificate that says CJC-1295 without saying whether the maleimide is present hasn't yet named the brief.

In short. Native GHRH is meant to work over a tiny local distance. In general blood it dies fast. The analogue cheats that death just enough, then stops.

D-Ala2 is the first and the most famous of the four. Replacing L-alanine at position 2 with its D-enantiomer removes the scissile bond DPP-IV wants. The enzyme is stereoselective; a D-residue at P1 is a locked door. The rest of the N-terminus still occupies the transmembrane activating pocket, which is why D-Ala2 analogues retain agonism while surviving plasma. This is the same logic that put aminoisobutyric acid at position 8 of semaglutide, and the same logic that made exendin-4, with a glycine at position 2, a Gila-monster proof that DPP-IV resistance is evolvable. On a GHRH backbone the D-alanine is sufficient to move half-life from minutes into a longer window. It isn't sufficient, on its own, to tidy the rest of the twenty-nine-mer's chemical liabilities. Three further substitutions do that work. They aren't decoration, and they aren't a potency contest against somatropin, which is a different receptor. They're how a twenty-nine-mer remains a twenty-nine-mer in a tube and in plasma long enough to be a pulse.

In short. Swapping the second amino acid to its mirror-image form stops DPP-IV cutting the chain. That single change is why the analogue survives long enough to work.

Gln8, Ala15 and Leu27 are the other three, and each earns a named sentence. Position 8 in native GRF is asparagine; asparagine rearranges and deamidates, a slow chemical death that you'll meet if you leave a reconstituted native sequence on the bench. Glutamine at 8 reduces that rearrangement. Position 15 is glycine in the native twenty-nine-mer; alanine there stabilises a helical stretch that the receptor likes, and the substitution is one of the reasons modified GRF isn't a weaker copy of GRF(1–29) but a tidied one. Position 27 is methionine in the native chain; methionine oxidises, and oxidation is how a perfectly synthesised peptide becomes a mixture after air and time. Leucine at 27 removes that sulphur. D-Ala2, Gln8, Ala15, Leu27: four edits, four liabilities, one backbone that still occupies GHRHR with full efficacy. That tetrasubstituted peptide is what the trade calls mod GRF 1–29, and what this catalogue files as CJC-1295 without DAC. The sequence is the product. The absence of the maleimide is the other half of the product.

In short. Three further amino-acid swaps stop the chain falling apart by deamidation, unfolding or oxidation. Together with the mirror-image alanine, they define this analogue.

The half-life that results sits on the order of tens of minutes rather than minutes, and rather than days. Tens of minutes is still a pulse on a somatotroph's clock. A nocturnal GH burst, in Veldhuis's deconvolutions, has a width measured in minutes to a short run of tens of minutes, not in hours of unrelieved tone. An analogue that occupies GHRHR across that width, then falls, is asking what a slightly prolonged physiological pulse does to burst mass, to the readily-releasable pool, and to the hepatic STAT5b programme when troughs are still allowed. That's a different question from what a daily recombinant GH bolus does, and a different question again from what a weekly albumin conjugate does. The substitutions were chosen to land in that middle window. They weren't chosen to win a half-life contest against an incretin. GHRH that lasts a week isn't better GHRH. It's flattened GHRH, and the liver can tell. The whole reason this analogue exists as a catalogue object is that window.

In short. After the four swaps, the analogue lasts tens of minutes. That is long enough to be useful and short enough that quiet gaps between bursts can still happen.

DAC is Drug Affinity Complex, ConjuChem's covalent half-life trick. The chemistry is an N-ε-maleimidopropionyl-lysine on a GHRH-analogue backbone. The maleimide Michael-adds to cysteine 34 of circulating albumin, a free thiol that peptide chemists have been aiming at for decades because albumin's own half-life is measured in weeks. Once conjugated, the peptide rides albumin for days. Clearance slows. Occupancy at GHRHR never quite returns to a trough. The original branded CJC-1295 was this conjugate. Papers that say CJC-1295 and mean the ConjuChem molecule are talking about the albumin adduct, not about tetrasubstituted GRF(1–29) sitting free in plasma. The trade then started selling the unconjugated tetrasubstituted twenty-nine-mer as CJC-1295 without DAC, which is how a catalogue ends up with a name that is a negation. The negation is the scientific sentence. Without the maleimide, modified GRF(1–29) remains a short-acting GHRH analogue that can still pulse. That's the version on the shelf, and it's the version we keep naming in full so the conjugate cannot sneak back in under the shorter name.

In short. DAC is a chemical hook that glues the peptide to albumin for days. Without that hook, the analogue stays short-acting. That absence is the whole point.

Albumin conjugation is a beautiful trick for a weekly incretin. It's the wrong trick if the message you want is a somatotroph pulse. Semaglutide, tirzepatide and retatrutide use a reversible fatty-acid handle so albumin carries them through the week; the lipid can come off, the reservoir is large, the receptor sees days of tone because the indication asked for days of tone. DAC is covalent rather than reversible, a Michael adduct rather than a hydrophobic parking brake, but the pharmacokinetic idea is cousin to that handle: make the peptide as long-lived as the protein it rides. GHRH, in life, isn't a weekly hormone. It's a portal pulse. Gluing it to albumin asks what happens when you take a pulse-generator's ligand and present it as a drip. That question is lawful. It's also a different question from what a slightly prolonged pulse does. Treating the with-DAC and without-DAC molecules as two strengths of one reagent is how you fail the Veldhuis heading, the STAT5b heading and the sexual-dimorphism heading in a single table footnote.

In short. Sticking a peptide to albumin is a clever way to make a weekly drug. Growth-hormone releasing hormone is not a weekly signal, so that trick changes the question.

Teichman, Neale, Lawrence, Gagnon, Castaigne and Frohman, Journal of Clinical Endocrinology and Metabolism, 2006, 91: 799–805, is the paper the conjugate owes you. A single subcutaneous dose of CJC-1295 with DAC produced multi-day elevation of GH and of IGF-1 in healthy adults. The tone was continuous rather than pulsatile. IGF-1 stayed up. That's a real result, in people, with a characterised albumin-conjugating analogue, and it answers the question ConjuChem asked: can you occupy GHRHR for days and move the hepatic integral. You can. The liver wrote IGF-1. What the liver did not write, because nobody asked it to in that design, is a Veldhuis burst series with troughs. Subsequent clinical development of the conjugate did not produce a licensed GHRH medicine; tesamorelin, a different analogue, took that job. The 2006 paper remains the existence proof for flattened GHRH tone. It's also the existence proof that flattened tone is a different object from modified GRF(1–29) without the maleimide. We picked the pulse-length ligand because of that difference, not because of a catalogue whim.

In short. A 2006 study showed that the albumin-glued version keeps growth hormone and IGF-1 raised for days after one dose. That is a flattened signal, not a burst.

Johannes Veldhuis spent a career showing that growth hormone is a digital signal. Deconvolution of frequent-sampled plasma GH, in humans and in animals, yields discrete bursts superimposed on a low interpulse baseline. Most of the mass is in the bursts. Most of the bursts, in a healthy adult, cluster after sleep onset, in slow-wave sleep, with a smaller daytime population. Amplitude falls with age, with abdominal adiposity, with hyperglycaemia. Amplitude rises with fasting, with oestradiol in some protocols, with a GHRH or secretagogue challenge. The pattern is the message. A single morning clinic GH is almost uninterpretable without an IGF-1, and even IGF-1 is an integral, not a pulse photograph. The papers sit in Journal of Clinical Endocrinology and Metabolism, in Endocrine Reviews, in a run of American Journal of Physiology pieces that a generation of fellows were handed. If you report GH as a continuous infusion or as a daily subcutaneous bolus and then talk as if you'd reproduced physiology, you haven't read Veldhuis. This analogue exists so that reading still has a reagent.

In short. Growth hormone comes in bursts, mostly at night. Veldhuis showed the pattern itself carries the message. A flattened dose is a different signal from a pulse.

Sleep is the largest physiological gate. Slow-wave sleep and the first nocturnal GHRH-permissive window coincide; deprive the slow waves and the GH peak shrinks. That's why night-time sampling exists, and why a daytime secretagogue challenge is a different probe from a nocturnal endogenous pulse. Thyroid hormone is permissive for GH synthesis. Glucocorticoids, in excess, suppress the axis at hypothalamus and pituitary; in replacement they are allowed. Sex steroids shape amplitude and frequency. Free fatty acids suppress GH release, one of the reasons obesity is a low-GH state. Ghrelin and fasting push the other way. Hyperglycaemia suppresses GH and will blunt a GHRH or secretagogue challenge, which is why a fed animal and a fasted animal aren't the same assay. The somatotroph isn't an isolated oscillator. It's a cell reading a hypothalamic ratio, a metabolic plasma, and a sleep clock. A tetrasubstituted twenty-nine-mer occupies one receptor in that village. Claiming the analogue 'is a pulse' without saying what the rest of the village was doing is a half-sentence.

In short. Sleep, sugar, fat, thyroid and fasting all gate these bursts. The analogue occupies one receptor; the rest of the body still has a vote.

Sampling is the unglamorous half of pulsatility, and it is where analogue papers most often cheat. A single clinic GH, drawn at nine in the morning, reports a trough more often than a peak and cannot distinguish deficiency from a nadir between bursts. Frequent sampling, every ten or twenty minutes overnight, is how Veldhuis deconvolved mass and frequency; it is also how you actually prove a pulse if that's the claim. IGF-1 is the integral: a hepatic average over hours, useful, and blind to whether the night was three large bursts or a flattened plateau. IGFBP-3 and the acid-labile subunit are slower integrals still. Occupy GHRHR with a thirty-minute analogue and then draw IGF-1 at a week, and you've measured the liver's running mean, not the somatotroph's burst. Draw GH at twenty-minute intervals around the dose if the question is the pulse. Draw IGF-1 if the question is the hepatic programme. Name which integral you meant. The two numbers don't substitute for each other, and a conjugate that keeps IGF-1 up for days can look 'stronger' on the slower integral while having abolished the faster one.

In short. One morning blood test for growth hormone is usually a quiet gap. Frequent samples show bursts. IGF-1 averages hours of liver output and hides those bursts.

Continuous growth hormone isn't pulsatile growth hormone at the liver. Hepatocytes reading a pulsatile STAT5b phosphorylation write IGF1, ALS and IGFBP3, the ternary-complex programme that circulating IGF-1 actually travels in. Hepatocytes reading a flattened GH tone write a different programme: more insulin antagonism, a different lipid-gene set, less of the IGF pattern many protocols thought they wanted. Receptor down-regulation contributes. SOCS2, a STAT5b target, feeds back and shuts the receptor down when occupancy is unrelieved. Jørgensen, the older rodent infusion studies, and the clinical experience with continuous subcutaneous GH pumps all point the same way. In the rat, a three-hour GH infusion and a pair of pulses matched for area-under-the-curve don't write the same cytochrome P450 genes. Pattern is information. Flatten it and you've changed the ligand even if the amino-acid sequence of GH is identical. That sentence is the design constraint for every GHRH analogue, and it is why this catalogue stocks CJC without the Drug Affinity Complex.

In short. The liver reads growth-hormone bursts as one gene programme and a continuous drip as another. Flatten the pulse and you change the message.

Sexual dimorphism of the pulse isn't a footnote, and it is another reason two CJC molecules are two questions. Male rodents fire large, regular nocturnal GH bursts against a near-silent baseline. Female rodents run a more nearly continuous, lower-amplitude tone. The liver reads those two patterns as two programmes. A classic molecular signature: male-pattern GH, in the rat, induces some cytochrome P450 genes (CYP2C11) and suppresses others (CYP2C12); female-pattern GH does the reverse. STAT5b pulsing versus STAT5b occupancy that never quite returns to baseline is a large part of the mechanism. Knock out STAT5b and the male-specific liver programme collapses toward female. Waxman, Norstedt, Mode and others built that literature. Humans are less cartoonishly dimorphic than rats, which is a species sentence this journal keeps making, but the principle survives: women have more frequent, smaller pulses and a higher interpulse baseline; men have larger, less frequent bursts. A pulse-length GHRH analogue can in principle respect that dimorphism. An albumin-conjugated analogue cannot, because it has already chosen the female-shaped, never-quite-baseline tone as its pharmacokinetic fate.

In short. Males and females fire growth hormone in different patterns, and the liver reads those patterns as different genes. A week-long analogue erases that difference.

Tesamorelin is a trans-3-hexenoyl GRF(1–44), Egrifta in the United States, licensed for reduction of excess abdominal fat in HIV-associated lipodystrophy. The hexenoyl cap is a different DPP-IV-resistance trick from D-Ala2: an acyl group on the N-terminus rather than a stereochemical swap at position 2. The backbone is the full forty-four rather than twenty-nine. Falutz, Allas, Blot and colleagues ran the trials that earned the indication; New England Journal of Medicine 2007 is the paper most people mean. IGF-1 rose. Visceral adipose tissue fell on imaging. Glucose had to be watched, as you would expect when you raise GH tone in adults. Daily subcutaneous dosing of a still-relatively-short analogue is closer to a pulse series than a weekly albumin conjugate is, which is why tesamorelin and CJC-with-DAC shouldn't be collapsed into one sentence either. The licensed molecule is the neighbour this essay is obliged to name so that a research vial isn't mistaken for it. Same receptor family. Different backbone, different cap, different legal class, different fridge.

In short. Tesamorelin is a licensed GHRH medicine for a specific fat-distribution problem in HIV. It proves the receptor can be a drug. It is not this research analogue.

Existence proof is a phrase worth keeping, because the alternative is to treat a research twenty-nine-mer as if it had a marketing authorisation it does not have. Tesamorelin demonstrates that GHRHR is drug-able, in a named indication, under a regulator, with pharmacovigilance, a device and a dose. That demonstration is valuable if you work on this receptor. It doesn't transfer its label onto modified GRF(1–29). Indication, authorisation and a package insert sit on one side of the sentence. Sequence, a certificate of analysis and a reconstitution kit sit on the other. Eliding the gap sells a neighbourhood as an address. The axis is interesting enough, and the analogue is distinct enough, that the elision is unnecessary as well as unlawful as a claim. A catalogue that stocks a pulse-length analogue next to a receptor that already has a licensed ligand has a duty to keep those objects labelled as two objects. We'll keep doing that, including in the last paragraph, once.

In short. A licensed GHRH drug shows the receptor is a real medicine target. That does not make the laboratory twenty-nine-mer the same product, or the same legal object.

Naming neighbours is a habit worth keeping across the catalogue. Retatrutide's neighbours are tirzepatide and semaglutide; the research vial is the published LY3437943 structure, not Lilly's pen. Somatropin's neighbour is every recombinant GH medicine on an endocrine ward; the research 191-mer is the same amino-acid sequence, labelled for a different job. Tesamorelin is the GHRH-analogue neighbour. Modified GRF(1–29) without DAC is the pulse-length ligand one step upstream of that, HPLC-characterised, for the bench. The hexenoyl cap and the D-alanine are two answers to DPP-IV; the forty-four and the twenty-nine are two answers to how much C-terminus the ectodomain needs. Daily tesamorelin is a pulse series with a medicine's responsibilities. Weekly DAC-CJC was a flattened-tone experiment that did not become a label. Catalogue CJC is the tetrasubstituted twenty-nine-mer that still troughs. Three objects. One receptor family. If you can't tell them apart you'll attribute the wrong clock to the wrong chain, and then be surprised when IGF-1, glucose and a pulse deconvolution refuse to agree.

In short. Three GHRH-family objects exist: a licensed daily medicine, a long-acting albumin conjugate, and this short laboratory analogue. Same receptor family, three clocks.

Ghrelin is the third speaker on the somatotroph, and it isn't hypothalamic in origin for most of its circulating mass. Kojima, Hosoda, Date, Nakazato, Matsuo and Kangawa, Nature 1999: a 28-residue peptide from the stomach, uniquely octanoylated on serine 3 by ghrelin O-acyltransferase, occupying the receptor that Howard, Smith and colleagues had cloned three years earlier as an orphan growth-hormone secretagogue receptor. The acylation is obligatory for GHS-R1a agonism. Des-acyl ghrelin circulates in larger amounts and is a different conversation. At the pituitary, GHS-R1a is expressed on somatotrophs and synergises with GHRH. In the arcuate, the same receptor sits on NPY/AgRP neurons and is the reason ghrelin is an orexigenic signal as well as a secretagogue. Vagal afferents carry a third copy of the story. One ligand, several addresses, one G protein family. A catalogue pentapeptide that occupies GHS-R1a will inherit that geography whether a protocol only sampled GH or not. Modified GRF(1–29) doesn't occupy that receptor. It occupies GHRHR. The two ligands are how you isolate the two locks.

In short. Ghrelin is a stomach hormone that also raises growth hormone, through a different receptor. This GHRH analogue does not occupy that second receptor.

GHS-R1a is a class-A GPCR, rhodopsin-like. The dominant coupling is Gq/11: phospholipase C, PIP2 cleavage, IP3, a calcium rise from stores and from the plasma membrane. A Gi component is real and is part of why the electrophysiology of a somatotroph seeing ghrelin isn't a carbon copy of one seeing GHRH. Synergy with GHRH is the physiological point of GHS-R1a on the somatotroph. In hypothalamic–pituitary clamp experiments, a GHRH pulse in the presence of a secretagogue produces a much larger GH burst than GHRH alone; a secretagogue in the absence of GHRH produces a smaller one. The large nocturnal pulses that Veldhuis deconvolved are, on this picture, a GHRH event amplified by ghrelin tone and permitted by a somatostatin trough. Two receptors, two G proteins, one granule. That's why co-application is how pituitary slices release the large pulses textbooks draw, and why if you apply both ligands you have to name both concentrations. Gs versus Gq/Gi isn't a stacking tip. It's the reason the two microphones exist as two microphones.

In short. The ghrelin receptor raises calcium by a different G protein from GHRH. When both receptors are on, the pituitary burst is larger than either signal alone.

Ipamorelin is Aib-His-D-2-Nal-D-Phe-Lys-NH2, the selective GHS-R1a pentapeptide this desk already wrote up at Cell length. Raun, Hansen, Nielsen, Heinig, Andersen, Thøgersen, Ankersen and Madsen, European Journal of Endocrinology, 1998, 139: 552–561. In vitro, on rat pituitary cells, it released GH. In vivo, in swine and in rats, plasma GH rose. ACTH, cortisol and prolactin did not, at doses that were effective for GH, in contrast to GHRP-6 and hexarelin run in the same protocols. That last clause is why it is the partner analogue people reach for when they want GHS-R1a without a stress-axis confound. Partner is a dangerous word. The two peptides occupy two receptors. Combined, they recapitulate the large pulse the textbooks draw. Combined without naming both concentrations, they become a stack, and a stack is a purchasing habit rather than an experiment. The papers that combined GHRH and a secretagogue in pituitary slices named both receptors and both doses. That's the standard. We stock both sequences. We won't help you write the sentence that pretends they are one ligand.

In short. Ipamorelin is a five-amino-acid partner at the ghrelin receptor that raises growth hormone without much stress-hormone noise. Two peptides, two receptors, not one mixture.

Bowers spent the 1980s making smaller, stronger peptides that released GH from pituitary cells without being GHRH. GHRP-6 worked, and it also moved ACTH, cortisol and prolactin, which is a messy experiment if the question was isolated growth-hormone release. Hexarelin did the same circus with more potency. When Smith's group cloned GHS-R, those ligands had a named target; they still had the off-axis baggage. The secretagogue field then split into cleaner tools and louder ones. A louder one isn't a better partner for a GHRH analogue. It's a partner plus a cortisol confound that will change the hepatic programme you thought you were reading as an IGF-1 effect. If you wanted GHRHR plus GHS-R1a, you wanted modified GRF(1–29) and ipamorelin, each characterised, each named, each at a stated concentration. If you wanted only GHRHR, you wanted the twenty-nine-mer and a quiet secretagogue receptor. Selectivity is how you know which G protein did the work. Circus is how you stop knowing.

In short. Older ghrelin-receptor peptides also shoved stress hormones around. A clean partner matters, because extra cortisol will scramble the liver readout you thought was growth hormone.

CJC without DAC asks a precise question: what does a slightly prolonged GHRH pulse do to somatotrophs, to GH burst mass, and to the hepatic STAT5b programme when troughs are still allowed. That isn't what ipamorelin asks. Ipamorelin asks what selective GHS-R1a agonism does to the same granule, and to arcuate and gastric addresses, without dragging ACTH and prolactin into the table. Recombinant somatropin asks the GH receptor itself, skipping the hypothalamus and the pituitary, and the answer will depend on whether you dose it as a pulse or as a drip. IGF-1 LR3 bypasses the pituitary and the liver and asks the tyrosine kinase on a myotube or a hepatocyte, with binding proteins taken out of the fight. Four ligands, four receptors, four questions. The axis essay on this desk is the wiring they share. This essay is the first microphone, at the length the tetrasubstituted twenty-nine-mer deserves. Confuse the four and you're assembling a stack. A stack isn't an experiment. Attribution is the job.

In short. This analogue asks what a slightly longer GHRH burst does, while quiet gaps remain. The other related peptides ask different receptors. Mixing them hides which one worked.

A dish isn't a somatotroph in a sleeping human, and a somatotroph in a sleeping human isn't a hepatocyte. Species is a variable: rodent sexual dimorphism of GH pattern is sharper than human; GHS-R1a constitutive activity and tissue distribution aren't identical across mammals; DPP-IV activity in a tube of plasma isn't DPP-IV on an endothelial surface in a portal circuit. Concentration is a variable: nanomolar in a well isn't a plasma free-fraction after proteases, first-pass and dilution have had their turn. DPP-IV will still try to eat an unmodified GHRH even in a tube if plasma is present, which is why the D-alanine isn't optional in any protocol that pretends to be using this analogue. The pulse-length GHRH analogue is how you isolate the GHRHR floor. It isn't how you skip floors. Pathophysiology, in the genome-to-function essay on this desk, is receptor then cell then tissue then organism. Apply the twenty-nine-mer and measure GH, then IGF-1, then a composition endpoint, and you've walked the floors. Apply four analogues at once and measure a waist, and you haven't.

In short. A cell dish, a rat and a person are three different systems. Use this analogue to isolate one receptor, then measure the next step down, in order.

Sequence identity is the only honest link between a catalogue vial and a paper. Modified GRF(1–29) without DAC is a defined tetrasubstituted 29-mer. HPLC and mass spectrometry are how we know that chain is in the cake, and how you know the maleimide is absent. A certificate that cannot show a main peak and a mass isn't yet a microphone; it's a rumour about a white powder. The kit in the box is bacteriostatic water and syringes so reconstitution is a documented step rather than an argument. None of that is a protocol for combining this analogue with a secretagogue, with somatropin, or with IGF-1 LR3. It's the minimum a research reagent owes a write-up that will have to put the catalogue number next to a concentration. Same sequence as the papers name, characterised, sitting on a shelf because GHRHR is a named protein and the pulse is a named design constraint. Confirm the mass. Then run the assay you can actually name.

In short. The vial is a named 29-amino-acid chain, checked by chromatography and mass. That identity is what lets a laboratory paper cite it honestly.

Somatropin as a comparison has a flattening problem of its own, even without DAC. A daily subcutaneous bolus of recombinant GH doesn't reproduce nocturnal pulsatility. It produces a broad plasma peak and a long tail, a pattern closer to a drip than to a Veldhuis burst, and the liver notices. Children with GH deficiency still grow on that regimen, which is one of the cleaner endocrine success stories of the late twentieth century, because a growing epiphysis will accept a flattened IGF-1 rise. Adults with true deficiency shift composition on it. Healthy adults given the same flattened signal are a different population, and acromegaly remains the experiment of nature for what chronic excess does to soft tissue, insulin sensitivity and myocardium. The research 191-mer is the ligand those programmes used. Dosing it as if it were a nocturnal pulse is a claim the pharmacokinetics will not support. If the question needs a pulse generated by the somatotroph, with somatostatin still in the contest, the pulse-length GHRH analogue is the microphone, not a larger IU count of somatropin.

In short. Daily growth-hormone injections are a broad peak, not a night burst. If the experiment needs the pituitary still in charge, this analogue is the tool, not more growth hormone.

IGF-1 LR3 is the other neighbour people drag into a GHRH sentence, and it belongs one floor further down. Francis, McDougall, Bagley, Ballard and colleagues made Long Arg3 IGF-1 by substituting Glu3 for arginine and adding a thirteen-residue N-terminal extension. IGF-binding-protein affinity collapses. IGF1R agonism remains. In serum-containing culture the analogue is the ligand the myoblast actually sees. It doesn't occupy GHRHR. It doesn't occupy GHR. It occupies a receptor tyrosine kinase, and glucose belongs in that protocol because hybrid insulin receptors are real. Reconstituting modified GRF(1–29) and LR3 into one experiment mixes a class-B GPCR on a somatotroph with an RTK on a myotube. Lawful, if both questions are named. Unlawful as attribution, if a single waist measurement is then credited to 'the GH axis'. The 83-mer has its own essay. This twenty-nine-mer has this one. Walk GHRH to GH to IGF-1, in that order, if the axis is the object. Skip to the kinase if the kinase is the object. Write which skip you made.

In short. A lab form of IGF-1 talks to a different receptor on muscle and other cells. It is not a GHRH analogue, and it does not answer the same question.

Modified GRF(1–29) without DAC is DPP-IV-resistant GHRH that still pulses. Native GHRH is a 44-residue hypothalamic peptide; GRF(1–29)-NH2 retains full agonism at GHRHR, a class-B GPCR coupled to Gs–cAMP–PKA and L-type Ca2+ influx in somatotrophs, triggering GH exocytosis. DPP-IV cleaves the Ala2–Asp3 bond within minutes in plasma. The tetrasubstituted analogue typically carries D-Ala2, Gln8, Ala15 and Leu27 to resist DPP-IV and oxidation while preserving receptor efficacy, yielding a half-life on the order of tens of minutes rather than days. CJC-1295 with DAC, N-ε-maleimidopropionyl-Lys on a similar backbone, was ConjuChem's albumin-conjugating analogue; Teichman 2006 showed multi-day GH and IGF-1 elevation after a single dose, continuous rather than pulsatile tone. Tesamorelin, a trans-3-hexenoyl GRF(1–44), is the FDA-licensed GHRH analogue for HIV-associated lipodystrophy, and is the clinical existence proof that this receptor is drug-able. Synergy with GHS-R1a, the ipamorelin microphone, is two G proteins on one granule. Veldhuis is why the pulse is the design constraint. Those sentences are the molecular field this essay was asked to keep, written out at the length they need.

In short. This analogue is a short, enzyme-resistant GHRH copy that still comes in bursts. The long-acting glued version and the licensed medicine are different objects.

The neighbouring essays take the rest of the map. The growth-hormone axis, properly explained: four microphones, four questions, the wiring this analogue sits on. Ipamorelin: Raun's tables, the pentapeptide sequence, the failed ileus programme as a reminder that selectivity isn't a universal drug. Somatropin: the 191, JAK2–STAT5b, adult-GHD composition trials, acromegaly as caution. IGF-1 LR3: the 83-mer, the Arg3 substitution, the dish that actually sees the kinase, glucose in the protocol. How peptides talk to cells: occupancy, amplification, arrestin, the class-B and class-A distinction this analogue uses on one side of a synergy. Pathophysiology: genome to function, floors you don't skip. Read those if you're holding a different vial, or if you wanted the axis rather than the analogue. Stay here if you wanted to know why the maleimide is absent, why tesamorelin is named, and why tens of minutes is a scientific number rather than a compromise. The athlete in the opening figure is an organism-level readout. The readout is late. GHRHR is early.

In short. Other essays cover the full hormone axis and the partner peptides. This one is why the short GHRH analogue exists, and why the long-acting hook was left off.

Protocols, doses and combinations live in the papers that already ran GHRH analogues, secretagogues, recombinant GH and IGF-1 analogues in animals and in dishes — PubMed, with concentrations, sampling intervals and exclusion criteria. Go there if you're running an experiment. Stay here if you wanted the analogue explained at the depth a Cell desk would allow a review. Tesamorelin remains the licensed GHRH analogue in its indication. Recombinant somatropin remains a medicine in diagnosed deficiency. The tetrasubstituted twenty-nine-mer remains a characterised ligand for GHRHR, pulse-length by design, sitting next to a receptor whose physiology was worked out before any of us were stocking it. The axis will still pulse tonight, whether or not anyone opened a vial, because the hypothalamus and the stomach and the somatotroph weren't waiting for a chromatogram. The figure is a late readout of that pulse, of hepatic IGF-1, and of an IGF1R on bone and muscle. The receptor was early. The absence of the maleimide was the point.

In short. This is the explanation, not a dosing plan. The pituitary will still release growth hormone in bursts tonight, whether or not anyone uses the analogue.